Comprehensive Cancer Centers of Nevada Physicians Play Key Role In Authorship Of Prestigious Cancer Report

*Publication highlights cancer research advances of the past year*

**Henderson, Nev. (April 10, 2013)** — Three physicians from Comprehensive Cancer Centers of Nevada (CCCN), an affiliate of The US Oncology Network, made major contributions to the American Society of Clinical Oncology’s (ASCO) annual review of significant cancer research. Every year, ASCO conducts an independent review of cancer research to highlight emerging trends in the field and to identify research with the greatest potential impact on patients' lives. This year’s report, “Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer,” was edited by CCCN medical oncologist, Nicholas J. Vogelzang, MD, FASCO. Two other medical oncologists with the practice, Fadi Braiteh, MD, CPI, and Wolfram Samlowski, MD, FACP, also made major contributions to the publication.

Every year hundreds of clinical research studies focusing on cancer are published. Keeping track of the most important advances in the field can be a daunting task. The ASCO Report is eagerly anticipated each year, as it is a valuable reference tool for many busy professionals in the medical field. This year’s Report covers 87 studies, 17 of which are designated as major advances that are practice changing. Chief among the advances are important developments in the areas of personalized medicine, screening, and overcoming treatment resistance.

Drs. Vogelzang, Braiteh and Samlowski were part of an elite editorial board of prominent oncologists around the country who were selected to help with the publication based on their expertise in areas pertinent to various sections of the Report. Dr. Vogelzang is a renowned medical oncologist, cancer researcher and an expert in genitourinary oncology and mesothelioma who has authored numerous peer-reviewed articles, book chapters and abstracts and has given hundreds of lectures to his peers. Dr. Braiteh has co-authored more than 40 peer-reviewed articles, abstracts and book chapters, and has expertise in gastro-intestinal oncology, thoracic malignancies and personalized drug development. He frequently lectures about clinical research, cancer and palliative medicine, and participates in numerous clinical trials. Dr. Samlowski is an expert in melanoma and renal cancer and has published more than 150 peer-reviewed articles, abstracts and book chapters, and taught oncology at various institutions throughout his career in addition to his clinical responsibilities. He currently has a teaching appointment at the University of Nevada, Reno.

“This annual review focuses on advances in clinical cancer research that could have the potential to change the industry and greatly impact the lives of patients,” said James Kilber, MBA, executive director, Comprehensive Cancer Centers of Nevada. “We are very proud to have three of our physicians contribute to such a prestigious report and have our practice and The US Oncology Network represented so well.”

**About Comprehensive Cancer Centers of Nevada**
Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning oncology group comprising medical, pediatric and radiation oncologists, breast surgeons, and 13 treatment centers and offices throughout Southern Nevada. The practice’s specialized physician and
nursing staff offers sophisticated diagnostic tools, the latest advances in cancer treatment, a full range of innovative, exclusive services and research-based care in a supportive and caring environment.

CCCN is accredited by the American College of Radiology, certified by the Quality Oncology Practice Initiative, and united in healing with The US Oncology Network (www.usoncology.com), one of the nation’s largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, CCCN is united with approximately 1,000 physicians and 10,000 cancer professionals nationwide. Comprehensive Cancer Centers of Nevada participates in clinical trials through US Oncology Research, which has helped to develop 46 FDA approved cancer therapies. The practice is also affiliated with the University of California Los Angeles (UCLA), which has enabled patients to remain in Southern Nevada while participating in clinical trials developed by UCLA faculty. For more information, visit the company's web site at www.cccnevada.com.

Media Contacts:
Lisa Santwer, Comprehensive Cancer Centers of Nevada
(702) 952-3379
Lisa.Santwer@usoncology.com

Claire Crye, The US Oncology Network
(281) 863-6783
Claire.Crye@usoncology.com

###